ES2530567T3 - Método para identificar un sujeto susceptible de desarrollar insuficiencia cardíaca determinando el nivel de galectina-3 o trombospondina-2 - Google Patents

Método para identificar un sujeto susceptible de desarrollar insuficiencia cardíaca determinando el nivel de galectina-3 o trombospondina-2 Download PDF

Info

Publication number
ES2530567T3
ES2530567T3 ES10186331T ES10186331T ES2530567T3 ES 2530567 T3 ES2530567 T3 ES 2530567T3 ES 10186331 T ES10186331 T ES 10186331T ES 10186331 T ES10186331 T ES 10186331T ES 2530567 T3 ES2530567 T3 ES 2530567T3
Authority
ES
Spain
Prior art keywords
level
determining
galectin
thrombospondin
identify
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10186331T
Other languages
English (en)
Spanish (es)
Inventor
Yigal M Pinto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Maastricht
Original Assignee
Universiteit Maastricht
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Maastricht filed Critical Universiteit Maastricht
Application granted granted Critical
Publication of ES2530567T3 publication Critical patent/ES2530567T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4728—Details alpha-Glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/321—Arterial hypertension
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
ES10186331T 2003-10-09 2004-09-27 Método para identificar un sujeto susceptible de desarrollar insuficiencia cardíaca determinando el nivel de galectina-3 o trombospondina-2 Expired - Lifetime ES2530567T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03078161A EP1522857A1 (en) 2003-10-09 2003-10-09 Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2

Publications (1)

Publication Number Publication Date
ES2530567T3 true ES2530567T3 (es) 2015-03-03

Family

ID=34306912

Family Applications (2)

Application Number Title Priority Date Filing Date
ES10186331T Expired - Lifetime ES2530567T3 (es) 2003-10-09 2004-09-27 Método para identificar un sujeto susceptible de desarrollar insuficiencia cardíaca determinando el nivel de galectina-3 o trombospondina-2
ES04765681T Expired - Lifetime ES2377012T3 (es) 2003-10-09 2004-09-27 Método para identificar un sujeto susceptible de desarrollar insuficiencia cardíaca determinando el nivel de galectina-3 o trombospondina-2

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES04765681T Expired - Lifetime ES2377012T3 (es) 2003-10-09 2004-09-27 Método para identificar un sujeto susceptible de desarrollar insuficiencia cardíaca determinando el nivel de galectina-3 o trombospondina-2

Country Status (14)

Country Link
US (5) US7888137B2 (enExample)
EP (4) EP1522857A1 (enExample)
JP (5) JP4840744B2 (enExample)
CN (2) CN1879022B (enExample)
AT (1) ATE532073T1 (enExample)
AU (2) AU2004284496C1 (enExample)
CA (2) CA2842308A1 (enExample)
CY (2) CY1112359T1 (enExample)
DK (2) DK1682907T3 (enExample)
ES (2) ES2530567T3 (enExample)
PL (2) PL1682907T3 (enExample)
PT (2) PT1682907E (enExample)
SI (2) SI2317324T1 (enExample)
WO (1) WO2005040817A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1522857A1 (en) * 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
AU2007301981A1 (en) * 2006-09-25 2008-04-03 Universiteit Maastricht Means and methods for diagnosing and/or treating a subject at risk of developing heart failure
WO2008091948A2 (en) * 2007-01-23 2008-07-31 University Of Virginia Patent Foundation Galectin-3-binding, protein as a biomarker of cardiovascular disease
CA2698899A1 (en) * 2007-09-17 2009-03-26 Bg Medicine, Inc. Assessing congestive heart risk in patients treated or potentially to be treated with a peroxisome-proliferator-activator-receptor-gamma agonist or a thiazolidinedione
CA2742265C (en) * 2008-10-29 2014-07-15 Bg Medicine, Inc. Galectin-3 immunoassay
EP2470911B1 (en) 2009-08-25 2016-04-20 BG Medicine, Inc. Galectin-3 and cardiac resynchronization therapy
WO2012003475A1 (en) 2010-07-02 2012-01-05 Bg Medicine, Inc. Statin therapy monitored by galectin- 3 measurement
US8703433B2 (en) * 2010-10-18 2014-04-22 Hideaki Hara Marker for amyotrophic lateral sclerosis, and use thereof
EP2460890A1 (en) 2010-12-01 2012-06-06 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Gpnmb/Osteoactivin as a drug target and biomarker in cardiac diseases
EP2671080A1 (en) * 2011-01-31 2013-12-11 BG Medicine, Inc. Use of galectin-3 for detecting and prognosing heart failure after acute coronary syndrome
EP2686689B1 (en) 2011-03-17 2019-08-07 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
AR086543A1 (es) * 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
JP6276701B2 (ja) * 2011-12-08 2018-02-07 エリアス・セラピューティクス・インコーポレイテッドＥｌｉａｚ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 血漿交換療法によるガレクチン−３レベルの低減
EP2900267B1 (en) * 2012-09-27 2019-05-15 Siemens Healthcare Diagnostics Inc. Cystatin c and galectin-3 as biomarkers for pulmonary arterial hypertension
CA2926480A1 (en) * 2012-11-15 2014-05-22 Tufts University Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor
AU2016207734A1 (en) 2015-01-18 2017-08-03 Diasorin S.P.A. Use of 1,25-dihydroxyvitamin D values in ratio with PTH as a prognostic biomarker
US10688565B2 (en) * 2015-05-28 2020-06-23 Kyocera Corporation Cutting tool
CN112553335A (zh) * 2020-12-17 2021-03-26 核工业总医院 肾细胞癌生物标志物及其应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4632901A (en) * 1984-05-11 1986-12-30 Hybritech Incorporated Method and apparatus for immunoassays
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
AU2684488A (en) * 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US6319676B1 (en) * 1995-05-02 2001-11-20 Carter Wallace, Inc. Diagnostic detection device and method
BE1010935A7 (nl) * 1997-02-19 1999-03-02 Delanghe Joris Richard Siegfri Fenotypering van humaan haptoglobine in serum of plasma door middel van quantitatieve agglutinatie met streptococcus antigenen.
US6210976B1 (en) * 1997-06-10 2001-04-03 Medlyte Diagnostics, Inc. Methods for early detection of heart disease
US20060166276A1 (en) * 1997-09-05 2006-07-27 Lung Health Diagnostics Pty Ltd Method of diagnosis and agents useful for same
IL134880A0 (en) * 1997-09-05 2001-05-20 Univ Southern Australia A method of diagnosis
AU751660B2 (en) * 1997-10-24 2002-08-22 Shionogi & Co., Ltd. Method for inhibiting decomposition of natriuretic peptides and improved method for assaying natriuretic peptides with the use of the same
WO1999051260A2 (en) * 1998-04-02 1999-10-14 Genentech, Inc. Treatment of cardiac hypertrophy
CA2359667C (en) * 1999-01-29 2009-10-20 Roche Diagnostics Gmbh Method of identifying n-terminal probnp
AU3704500A (en) * 1999-02-19 2001-01-22 University Of Iowa Research Foundation, The Diagnostics and therapeutics for arterial wall disruptive disorders
JP2003507076A (ja) * 1999-08-20 2003-02-25 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム 心臓の遺伝子発現の調節におけるｈｄａｃ４およびｈｄａｃ５
US20020081590A1 (en) 2000-02-04 2002-06-27 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
EP1358347A2 (en) 2000-04-05 2003-11-05 Incyte Genomics, Inc. Genes expressed in foam cell differentiation
KR100395254B1 (ko) * 2000-10-30 2003-08-21 (주)자리타 바이오텍 종양 발생 예측 키트
US7432060B2 (en) * 2000-11-09 2008-10-07 The Brigham And Women's Hospital, Inc. Methods for diagnosis of cardiovascular disease
AU2002220266A1 (en) * 2000-11-09 2002-05-21 Millennium Pharmaceuticals, Inc. Methods for the identification and the treatment of cardiovascular disease
DE60144493D1 (de) * 2000-12-08 2011-06-01 Curagen Corp Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
JP4035562B2 (ja) * 2001-01-31 2008-01-23 国立大学法人富山大学 ガレクチン−３誘導能を利用した物質のスクリーニング方法、肝の状態の診断方法およびこれらの方法を利用したキット
WO2002074911A2 (en) 2001-03-19 2002-09-26 Wisconsin Alumni Research Foundation Identification of gene expression alterations underlying the aging process in mammals
US20060019235A1 (en) 2001-07-02 2006-01-26 The Board Of Trustees Of The Leland Stanford Junior University Molecular and functional profiling using a cellular microarray
US7447594B2 (en) 2001-07-10 2008-11-04 Ocimum Biosolutions, Inc. Molecular cardiotoxicology modeling
US20030099958A1 (en) * 2001-09-05 2003-05-29 Vitivity, Inc. Diagnosis and treatment of vascular disease
GB0124145D0 (en) 2001-10-08 2001-11-28 Bayer Ag Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
US20060141493A1 (en) 2001-11-09 2006-06-29 Duke University Office Of Science And Technology Atherosclerotic phenotype determinative genes and methods for using the same
US7294652B2 (en) * 2002-05-13 2007-11-13 Arexis Ab Autoimmune conditions and NADPH oxidase defects
AU2003290537A1 (en) 2002-10-24 2004-05-13 Duke University Binary prediction tree modeling with many predictors and its uses in clinical and genomic applications
BR0316111A (pt) 2002-11-21 2005-09-13 Wyeth Corp Métodos para diagnosticar rcc e outros tumores sólidos
EP1431399A1 (en) * 2002-12-20 2004-06-23 Clinigenetics Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions
US6889083B2 (en) * 2003-04-21 2005-05-03 Medtronic, Inc. Atrial tracking recovery to restore cardiac resynchronization therapy in dual chamber tracking modes
WO2005020784A2 (en) 2003-05-23 2005-03-10 Mount Sinai School Of Medicine Of New York University Surrogate cell gene expression signatures for evaluating the physical state of a subject
WO2004111654A2 (en) 2003-06-06 2004-12-23 Ciphergen Biosystems, Inc. Serum biomarkers in ischaemic heart disease
US20050106100A1 (en) 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
EP1560025A3 (en) * 2003-10-03 2011-09-07 F. Hoffmann-La Roche AG Specific markers for diabetes
EP1522857A1 (en) * 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
DE10347436B4 (de) * 2003-10-13 2007-08-02 Johann Wolfgang Goethe-Universität Frankfurt am Main In vitro Verfahren zur Diagnose der kardiovaskulären Funktionalität von Blut-abgeleiteter zirkulierender Vorläuferzellen (BDP)
EP1720562A4 (en) 2004-01-15 2009-10-28 Scios Inc METHOD FOR TREATING CARDIAL REMODELING AFTER MYOCARDIAL DAMAGE
WO2006026074A2 (en) 2004-08-04 2006-03-09 Duke University Atherosclerotic phenotype determinative genes and methods for using the same
AU2006210794A1 (en) 2005-02-01 2006-08-10 Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Biomarkers for tissue status
US20070092886A1 (en) 2005-03-22 2007-04-26 Raymond Tabibiazar Methods and compositions for diagnosis, monitoring and development of therapeutics for treatment of atherosclerotic disease
US7632634B2 (en) 2005-04-15 2009-12-15 University Of Maryland Biotechnology Institute Method and assay for early diagnosis of prostate cancer
US9592970B2 (en) * 2008-07-17 2017-03-14 Toby D. Henderson Robotic gantry with end effector for product lifting
CA2742265C (en) * 2008-10-29 2014-07-15 Bg Medicine, Inc. Galectin-3 immunoassay
EP2470911B1 (en) * 2009-08-25 2016-04-20 BG Medicine, Inc. Galectin-3 and cardiac resynchronization therapy

Also Published As

Publication number Publication date
AU2004284496B2 (en) 2009-08-06
CA2842308A1 (en) 2005-05-06
ES2377012T3 (es) 2012-03-21
HK1101426A1 (en) 2007-10-18
CN102998458A (zh) 2013-03-27
SI1682907T1 (sl) 2012-03-30
EP1522857A1 (en) 2005-04-13
JP5789009B2 (ja) 2015-10-07
AU2009227844B2 (en) 2012-07-19
PT2317324E (pt) 2015-02-17
CN1879022B (zh) 2012-10-17
JP5580774B2 (ja) 2014-08-27
SI2317324T1 (sl) 2015-11-30
EP2317324B1 (en) 2014-11-12
US20130189716A1 (en) 2013-07-25
CY1112359T1 (el) 2015-12-09
US20080193954A1 (en) 2008-08-14
EP2919012A1 (en) 2015-09-16
WO2005040817A1 (en) 2005-05-06
US20110104722A1 (en) 2011-05-05
PL2317324T3 (pl) 2015-10-30
CA2542033A1 (en) 2005-05-06
AU2004284496A1 (en) 2005-05-06
CA2542033C (en) 2014-04-29
PT1682907E (pt) 2012-02-03
US20120220532A1 (en) 2012-08-30
JP2011177184A (ja) 2011-09-15
AU2009227844A1 (en) 2009-11-26
EP2317324A1 (en) 2011-05-04
CY1116147T1 (el) 2017-02-08
DK2317324T3 (en) 2015-02-16
CN102998458B (zh) 2015-07-22
ATE532073T1 (de) 2011-11-15
JP2015171365A (ja) 2015-10-01
EP1682907A1 (en) 2006-07-26
US20150037353A1 (en) 2015-02-05
AU2004284496C1 (en) 2010-03-04
JP2014115297A (ja) 2014-06-26
JP2007508527A (ja) 2007-04-05
US7888137B2 (en) 2011-02-15
HK1184534A1 (zh) 2014-01-24
DK1682907T3 (da) 2012-08-13
CN1879022A (zh) 2006-12-13
PL1682907T3 (pl) 2012-03-30
EP1682907B1 (en) 2011-11-02
US8084276B2 (en) 2011-12-27
JP2010279378A (ja) 2010-12-16
JP4840744B2 (ja) 2011-12-21

Similar Documents

Publication Publication Date Title
ES2530567T3 (es) Método para identificar un sujeto susceptible de desarrollar insuficiencia cardíaca determinando el nivel de galectina-3 o trombospondina-2
Monteiro et al. Quantitative histopathology of Oreochromis niloticus gills after copper exposure
DK1734368T3 (da) Annexin-autoantistoffer anvendt som markörer for lungecancer
ES2113546T3 (es) Metodos y estuches de diagnostico para determinar la toxicidad de un compuesto utilizando promotores de estres bacterianos fusionados con genes reporteros.
WO2008120684A1 (ja) 急性中枢神経障害の予後判定方法
ATE111228T1 (de) Verfahren zur überwachung des kollagenabbaus.
ATE415662T1 (de) Bestimmung der tatsächlichen zeit, die ein prozessor bei der ausführung eines codeteiles aufwendet
EP2293075A3 (en) Method for diagnosing neuro-degenerative disease
EA200500355A1 (ru) Способ обнаружения, характеристики и мониторинга углеводородных месторождений
ATE458201T1 (de) Methode zur beurteilung von rheumatoider arthritis durch bestimmung von anti-ccp und interleukin 6
EA200701602A1 (ru) Способ прогнозирования психических заболеваний, например аутизма и церебрального паралича
DE60016242D1 (de) Verfahren zur diagnose oder prognose von altersbedingter maculadegeneration
DE69809640D1 (de) Methode zum Nachweis eines Analyten durch Immunchromatographie
ATE555387T1 (de) Tests der molekularen oder subzellulären nähe unter verwendung von depolarisierung nach resonanzenergietransfer (daret)
ATE462001T1 (de) Markerproteine zur diagnose einer lebererkrankung und verfahren zur diagnose einer lebererkrankung damit
WO2009140390A3 (en) Serum markers for type ii diabetes mellitus
ATE550664T1 (de) Multiplex-screening auf lysosomale speicherkrankheiten (lsds)
CY1105025T1 (el) Αναλυση λεπτινης βασιζομενη στην ανιχνευση εκφρασης ang-2
DK1721162T3 (da) Fremgangsmåde til at bedömme rheumatoid arthritis ved at måle anti-CCP og serumamyloid A
ATE482398T1 (de) Verfahren zur stratifizierung von herzinsuffizienz
ATE392619T1 (de) Verfahren zur diagnose von synovialen oder osteoartikulären erkrankungen
BRPI0512336A (pt) métodos de diagnósticos para osteoporose
DE602005007817D1 (de) Analyse-Verfahren unter Verwendung von abgeschwächter Totalreflektion
ATE421693T1 (de) Proteine in der diabetes-proteomanalyse
WO2003068958A1 (fr) Procede d'analyse d'un acide nucleique specifiant un gene presentant une modification de son niveau d'expression liee a la schizophrenie